EVELYN DENNIS: Open Payments
NPI 1457963746 · SNELLVILLE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$769 in 46 payments from 7 companies in 2025. Trend: 2023 $669 · 2024 $956 · 2025 $769
Food & beverage: $769
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 8 | $234 |
| Teva Pharmaceuticals USA, Inc. | 21 | $145 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $111 |
| Otsuka America Pharmaceutical, Inc. | 5 | $89 |
| Janssen Pharmaceuticals, Inc | 3 | $76 |
| ABBVIE INC. | 3 | $62 |
| E.R. Squibb & Sons, L.L.C. | 2 | $52 |
Products named: INGREZZA, UZEDY, CAPLYTA, INVEGA SUSTENNA, VRAYLAR, COBENFY, ABILIFY MAINTENA, ABILIFY ASIMTUFII.
Industry payments across GA — which companies pay providers there.
